Professor Mark Rees is an Honorary Professor at the Institute of Life Science (ILS), Swansea University Medical School (SUMS). He spent 15-years at SUMS (2004-2019) where he led a successful neurology research group, was Director of ILS (2007-2012) and Founder/Director of the Wales Epilepsy Research Network (WERN, 2005-2015). He also established the Swansea Neurology Biobank (SNB) which is now part of several international consortia and driving SUMS research. He continues to chair and lead the SNB up until April 2020.
He gained his PhD at the Department of Molecular Haematology, University of Wales College of Medicine (1989-1994) and worked with Sir Mike Owen in Psychiatric Medicine, Cardiff University as a MRC Postdoctoral Fellow (1994-1999). In 1999, Professor Rees began a six-year academic post at the University of Auckland Medical School, New Zealand as a Senior Lecturer in Neurology Genetics. He has published over 115 peer-reviewed publications and has attracted over £21m of research investments in his career.
Professor Rees was Chair of the Epilepsy Research-UK (ERUK, 2011-2014) Scientific Advisory Committee in London and a Trustee of ERUK until 2019. He is a Fellow of the Learned Society for Wales (FLSW), the Royal College of Pathologists (FRCPath), the Royal College of Physicians (FRCPE), and the Royal Society of Biology (FRSB). He received a DSc from Swansea University and is also Honorary Fellow of the Association of British Neurologists. Professor Rees’s team were winners of the 2015 Swansea University Impact Awards in Health & Wellbeing.
In 2019, he joined as Deputy Executive Dean the Faculty of Medicine & Health (FMHS) at the University of Sydney (USYD) and is using his 30 years of experience to meet Faculty objectives. He co-ordinates the collaborative interaction between Faculty and the independent Medical Research Institutes (MRI’s), Sydney Local Health Districts and Multi-Disciplinary Initiatives (MDI’s) in conjunction with Deputy-VC of Research. He is also responsible for growing the biomedical, commercial and philanthropic capabilities of the FMHS 2019-2024.